↓ Skip to main content

Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma

Overview of attention for article published in Clinical Epigenetics, October 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
20 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma
Published in
Clinical Epigenetics, October 2017
DOI 10.1186/s13148-017-0412-9
Pubmed ID
Authors

Yulin Guo, Yaojun Peng, Dan Gao, Meiying Zhang, Weili Yang, Enqiang Linghu, James G. Herman, François Fuks, Guanglong Dong, Mingzhou Guo

Abstract

Hepatocellular carcinoma is the fifth most common malignancy and the third leading cause of cancer-related death worldwide. Dysregulation of HomeoboxD10 (HOXD10) was found to suppress or promote cancer progression in different cancer types. The function and regulation of HOXD10 remain unclear in human hepatocellular carcinoma (HCC). Primary HCC samples (117), normal liver tissue samples (15), and 13 HCC cell lines (SNU182, SNU449, HBXF344, SMMC7721, Huh7, HepG2, LM3, PLC/PRF/5, BEL7402, SNU387, SNU475, QGY7703, and Huh1) were included in this study. Methylation-specific PCR, flow cytometry, western blot, transwell, siRNA, and chromatin immunoprecipitation assays were employed. HOXD10 was methylated in 76.9% (90/117) of human primary HCC samples. HOXD10 methylation was significantly associated with vessel cancerous embolus, tumor cell differentiation, and the 3-year overall survival rate (all P < 0.05). The expression of HOXD10 was regulated by promoter region methylation. HOXD10 suppressed colony formation, cell proliferation, cell invasion and migration, and induced G2/M phase arrest and apoptosis in HCC cells. HOXD10 suppressed HCC cell xenograft growth in mice. HOXD10 suppresses HCC growth by inhibiting ERK signaling. HOXD10 is frequently methylated in human HCC, and the expression of HOXD10 is regulated by promoter region methylation. HOXD10 suppresses HCC cell growth both in vitro and in vivo. HOXD10 suppresses human HCC by inhibiting ERK signaling.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 25%
Student > Master 5 25%
Student > Bachelor 2 10%
Professor 2 10%
Other 1 5%
Other 3 15%
Unknown 2 10%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 7 35%
Medicine and Dentistry 4 20%
Pharmacology, Toxicology and Pharmaceutical Science 3 15%
Agricultural and Biological Sciences 2 10%
Nursing and Health Professions 1 5%
Other 0 0%
Unknown 3 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 September 2018.
All research outputs
#8,452,100
of 13,477,526 outputs
Outputs from Clinical Epigenetics
#488
of 666 outputs
Outputs of similar age
#181,165
of 312,353 outputs
Outputs of similar age from Clinical Epigenetics
#22
of 46 outputs
Altmetric has tracked 13,477,526 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 666 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 312,353 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.